Working groups
The Research Group Peritoneum is dedicated to the investigation and treatment of primary and metastatic tumours of the peritoneal surface. These include malignant mesothelioma, pseudomyxoma and peritoneal metastases, especially those originating from colorectal, gastric and pancreatic carcinomas. A particular focus has been set on preclinical research into tumour biology, as well as on clinical studies that contribute equally to the development of innovative therapies. The expansion of a clinical database and biobank facilitates the systematic collection of patient-specific data and samples for utilisation in both preclinical and translational research projects. Treatment strategies such as cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) are continuously being improved and used, benefiting from these findings. Integrating tumour biology, surgery and oncology enables the realisation of individualised therapy options for peritoneal diseases, which can lead to optimised therapy effectiveness and improved clinical outcomes.
Selected publications
Brandl A, and van Sandick JW (2024). Treatment of gastric cancer peritoneal metastases: role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg 111.
Rau B, Lang H, Koenigsrainer A, Gockel I, Rau HG, Seeliger H, Lerchenmueller C, Reim D, Wahba R, Angele M, Heeg S, Keck T, Weimann A, Topp S, Piso P, Brandl A, Schuele S, Jo P, Pratschke J, Wegel S, Rehders A, Moosmann N, Gaedcke J, Heinemann V, Trips E, Loeffler M, Schlag PM, and Thuss-Patience P (2024). Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial. J Clin Oncol 42, 146-156.
Dahlmann M, Gambara G, Brzezicha B, Popp O, Pachmayr E, Wedeken L, Pflaume A, Mokritzkij M, Gul-Klein S, Brandl A, Schweiger-Eisbacher C, Mertins P, Hoffmann J, Keilholz U, Walther W, Regenbrecht C, Rau B, and Stein U (2021). Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular signatures by a novel preclinical platform of matching pmCRC PDX/PD3D models. Mol Cancer 20, 129.
Research images
